PTO/SB/05 (11-00) e through 10/31/2002. OMB 0651-0032

Approve : U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademar Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No. First Inventor Chri		No.	01107.00140 s TORRANCE				
		Chr					
Title	USE OF ISOGENIC HUMAN CANCER CELLS FOR HIGH- THROUGHPUT SCREENING AND DRUG DISCOVERY						

(Only for new	nonprovisiona	applications un	der 37 C.F.R. 1	1.53(b)) L	xpress Maii i	Label No.			_ <i>Y</i>		
APPLICATION ELEMENTS						ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231					
See MPEP chapter 600 concerning utility patent application contents.											
		Form (e.g., PT d a duplicate for fe				7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
2. App	olicant claims	small entity st			8. Nuci	Nucleotide and/or Amino Acid Sequence Submission					
3. 🛛 Spe		 ment set forth be	Total Pages low)	33]	a. □ b. Sp	 (if applicable, all necessary) a. ☐ Computer Readable Form (CRF) b. Specification Sequence Listing on: 					
- Cro		to Related App				i. ☐ CD-ROM or CD-R (2 copies); or ii. ☐ paper					
		ding Fed sponso uence listing, a t			c. 🔲						
or a	Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention					ACCOMPANYING APPLICATIONS PARTS					
- Bri	ef Summary of	the Invention			9. 🔲	9. Assignment Papers (cover sheet & document(s))					
- De	et Description tailed Descript aim(s)	of the Drawings ion	(IT TIIOO)		10.	10. 37 C.F.R.§3.73(b) Statement Power of (when there is an assignee) Attorney					
- Ab	stract of the Di	sclosure			11. 🔲	11. English Translation Document (if applicable)					
4. Dra 5. Oath or De	wing(s) (35 (•	[Total Sheet Total Pages		12. 🗌	☐ Information Disclosure ☐ Copies of IDS Statement (IDS)/PTO-1449 Citations					
		ں d (original or d:		ر لـــــا	13. 🔲	13. Preliminary Amendment					
	•	ior application		3 (d))	14. 🗌						
(for a continuation/divisional with Box 18 completed)						(Should be specifically itemized) 15. Certified Copy of Priority Document(s)					
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)						(if foreign priority is claimed)					
named in the prior application, see 37 CFR						16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35					
_	1.63(d)(2) and 1.33(b). 3. Application Data Sheet. See 37 CFR 1.76						or its equivalent. 17. ☐ Other:				
						Othor	_				
				ox, and supp	ly the requisi	te informatior	n below and in a	preliminary amendment,			
or in an Applic ☐ Continua	_	eet under 37 Ci ☑ Divisional		nuation-in-par	t (CIP)	CIP) of prior application No:/					
Prior applic	ation information		niner			Group / Art Unit:					
under Box 5b.	is considered	a part of the di	sclosure of th	ne accompan	vina or divisi	ional applicat	rom which an oa ilon and is hereb the submitted a	th or declaration is supplied y incorporated by reference oplication parts.	; ∍.		
		······································	******	ORRESPO							
☐ Customer Number or Bar Code Label (Insert Customer No. or Atta				ttach har cod	e lahel here)	or 🗆 Co	rrespondence address below				
			Imsert Cast	omor tvo. or A	itadir bar coo						
Name											
Address –											
/\dd/035		***									
City	State						Zip Code				
Country			Telepi	hone			Fax				
Name (Print/Type) Lisa M. Hemmendinger			Registratio	n No. (Attorr	ney/Agent)	42,653					
Signature Lina N			2. Hem	neadik	e_		Date	September 25, 2001			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

١<u>ٿ</u> ĘŪ ţħ ٠Ō TU M